AlphaDBS System for Parkinsons Disease Receives CE Mark

AlphaDBS System is the first rechargeable deep brain neurostimulation system that can continuously record and interpret bioelectrical neuronal activity in the brain areas where stimulation is delivered reports Newronika, a spin-off of world-class neurological research center Policlinico of Milan and the University of Milan.

AlphaDBS’s proprietary sensing technology records noise-free local field potentials while electrical stimulation is delivered.

The AlphaDBS system is also capable of closed-loop stimulation in which the current delivered is automatically adjusted for the individual needs of each patient, a true revolution in DBS care and personalized medicine. This feature is currently under clinical evaluation. When available, it will be the most important innovation in the DBS field. The device also collects brain signals critical to developing new treatments using a first-of-its-kind telemonitoring platform between patients and physicians.

“The ability to collect real-time brainwave information from patients with Parkinson’s disease during electrical stimulation treatment provides clinicians with a unique opportunity to understand the disease process and how effective stimulation is while patients participate in normal activities of life,” said Lorenzo Rossi, co-founder and CEO of Newronika.

“DBS is an established treatment for treating Parkinson’s disease but there has been minimal innovation in how to deliver the therapy. The capability of AlphaDBS to collect real-time information from the brain with the potential to close the loop is a major advancement for a personalized therapy, which is only delivered when needed. Such an ‘on demand’ therapy holds the promise of better efficacy and less adverse effects than continuous stimulation,” according to Jens Volkmann, MD, Professor and Chairman Department of Neurology, University Hospital Würzburg, Germany.

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."